Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 16/20 | 1.00 |
| ▸ | CES1 | P23141 | 15/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | DAO | P14920 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1195835 | 1.00 | CES2 (1.00) | CES2CES1RAB9ADAOTSHR | |
| Benzil SCHEMBL2156589 | 0.97 | CES2 (1.00) | CES2CES1RAB9ADAOTSHR | |
| Benzil SCHEMBL28475956 | 0.97 | CES2 (1.00) | CES2CES1RAB9ADAOTSHR | |
| Benzil SCHEMBL7142843 | 0.97 | CES2 (1.00) | CES2CES1RAB9ADAOTSHR | |
| Benzil SCHEMBL9517636 | 0.97 | CES2 (1.00) | CES2CES1RAB9ADAOTSHR | |
| Benzil SCHEMBL66 | 0.97 | CES2 (1.00) | CES2CES1RAB9ADAOTSHR | |
| Benzil SCHEMBL9799726 | 0.93 | CES2 (0.93) | CES2CES1RAB9ADAOTSHR | |
| Benzil SCHEMBL1002038 | 0.93 | CES2 (0.93) | CES2CES1RAB9ADAOTSHR | |
| Benzil SCHEMBL1311689 | 0.93 | CES2 (0.93) | CES2CES1RAB9ADAOTSHR | |
| Benzil SCHEMBL10996187 | 0.93 | CES2 (0.93) | CES2CES1RAB9ADAOTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146548-A1 | AMIDE, ARYL SULFONAMIDE, ARYL UREA, AND a,b-DIKETONE DERIVED CARBOXYLESTERASE INHIBITORS, AND THEIR METHODS OF USE | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146548-A1 | AMIDE, ARYL SULFONAMIDE, ARYL UREA, AND a,b-DIKETONE DERIVED CARBOXYLESTERASE INHIBITORS, AND THEIR METHODS OF USE | CES1, BCHE, CES2 | CES2 3/4885CES1 1/4885RAB9A 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.